SYH2072 not checked
InnovStone Therapeutics Limited
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SYH2072 placebo tablets will be administered as a single or multiple oral doses.”In the company’s words, NCT07647783 on ClinicalTrials.gov
- Main trialPhase 2
- “SYH2072 is a highly selective aldosterone synthase inhibitor. This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of SYH2072 tablets in patients with uncontrolled hypertension (including patients with resistant hypertension) receiving stable treatment with two or more antihypertensive agents.”In the company’s words, NCT07911735 on ClinicalTrials.gov
Other drugs for Uncontrolled Hypertension
- BaxdrostatAstraZeneca · Phase 3
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- RalinepagUnited Therapeutics · Phase 3
- OrforglipronEli Lilly · Phase 3
- HCP1803-3Hanmi · Phase 3
Coming up3
- 1 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 22 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Feb 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 22 Jul 2027 | A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patients | |
| Phase 2Not yet recruiting | 1 Feb 2028 | SYH2072 Tablets in Participants With Primary Aldosteronism | |
| Phase 1Recruiting | 1 Feb 2027 | A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026